PaulIanniniMD

PubMed

• 22 citations
  A case series of macrolide treatment failures in community acquired pneumonia.
  Paul B. Iannini, Joseph A. Paladino, B. Lavin, Mendel E. Singer, Jerome J. Schentag> ;Journal of Chemotherapy. 2007 Oct 1
• 29 citations
  The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
  Paul B. Iannini> ;Current Medical Research and Opinion. 2007 May 8
• 10 citations
  Direct Costs in Patients Hospitalised with Community-Acquired Pneumonia After Non-Response to Outpatient Treatment with Macrolide Antibacterials in the US
  Joseph A. Paladino, Martin H. Adelman, Jerome J. Schentag, Paul B. Iannini> ;Pharmacoeconomics. 2007 Jan 1
• Medication options for the treatment of CAP.
  Lionel A. Mandell, Thomas M. File, Paul B. Iannini> ;American Family Physician. 2006 Nov 1
• 11 citations
  Adverse cutaneous reactions and drugs: a focus on antimicrobials.
  Paul B. Iannini, Lionel A. Mandell, J. Felmingham, G. Patou, G.S. Tillotson> ;Journal of Chemotherapy. 2006 Apr 1
• 6 citations
  Cutaneous adverse events and gemifloxacin: observations from the clinical trial program.
  Paul B. Iannini, Lionel A. Mandell, G. Patou, N. Shear> ;Journal of Chemotherapy. 2006 Feb 1
• Macrolide-resistant Streptococcus pneumoniae: clinical implications for the empiric treatment of community-acquired respiratory tract infections.
  Stephen A. Brunton, Paul Iannini> ;Medgenmed. 2005 Dec 7
• 16 citations
  Fluoroquinolone-Resistant Streptococcus pneumoniae, an Emerging but Unrecognized Public Health Concern: Is it Time to Resight the Goalposts?
  P. G. Ambrose, Darrin J. Bast, Gary V. Doern, Paul B. Iannini, Ronald N. Jones, Keith P. Klugman, Don E. Low> ;Clinical Infectious Diseases. 2004 Nov 15
• 33 citations
  Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.
  Octavian C. Ioachimescu, Adriana G. Ioachimescu, Paul B. Iannini> ;International Journal of Antimicrobial Agents. 2004 Nov 1
• 3 citations
  Respiratory fluoroquinolones: Differences in the details
  Lionel A. Mandell, Paul B. Iannini, Glenn S. Tillotson> ;Clinical Infectious Diseases. 2004 May 1
• 23 citations
  Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity.
  Juan-Pablo Caeiro, Paul B Iannini> ;Expert Review of Anti-Infective Therapy. 2003 Oct 1
• 2 citations
  Prevention and management of antibacterial resistance for primary care patients with respiratory tract infections.
  Paul B. Iannini> ;Southern Medical Journal. 2003 Oct 1
• 56 citations
  Emergence of fluoroquinolone resistance among Bacteroides species
  Yoav Golan, Laura A. McDermott, Nilda V. Jacobus, Ellie J. C. Goldstein, Sydney M. Finegold, Lizzie J. Harrell, David W. Hecht, Stephen G. Jenkins, Carl L. Pierson, Ri...> ;The Journal of Antimicrobial Chemotherapy. 2003 Aug 1
• 47 citations
  Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.
  Paul B. Iannini> ;Expert Opinion on Drug Safety. 2002 Jul 1
• 41 citations
  Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
  Joseph S. Bertino, Robert C. Owens, Timothy D. Carnes, Paul B. Iannini> ;Clinical Infectious Diseases. 2002 Mar 15
• 5 citations
  An updated safety profile of moxifloxacin.
  Paul B. Iannini, Lionel A. Mandell> ;Journal of Chemotherapy. 2002 Feb 1
• 9 citations
  Quinolone-induced QT interval prolongation: a not-so-unexpected class effect
  Paul B. Iannini> ;The Journal of Antimicrobial Chemotherapy. 2001 Jun 1
• 18 citations
  Reassuring safety profile of moxifloxacin.
  Paul B. Iannini, R. Kubin, C. Reiter, Glenn S. Tillotson> ;Clinical Infectious Diseases. 2001 Apr 1
• 11 citations
  Evaluating the risk of cardiac toxicity.
  Paul B. Iannini, Glenn S. Tillotson> ;Pharmacotherapy. 2001 Mar 1
• 73 citations
  Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.
  David R. Snydman, Nilda V. Jacobus, Laura A. McDermott, Stacey Supran, G J Cuchural, Sydney M. Finegold, Lizzie J. Harrell, David W. Hecht, Paul B. Iannini, S. Jenkins...> ;Antimicrobial Agents and Chemotherapy. 1999 Oct 1
• 41 citations
  Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
  David R. Snydman, Laura A. McDermott, G J Cuchural, David W. Hecht, Paul B. Iannini, Lizzie J. Harrell, Stephen G. Jenkins, J. Paul O'Keefe, Carl L. Pierson, John D. R...> ;Clinical Infectious Diseases. 1996 Dec 1
• 7 citations
  Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
  G J Cuchural, David R. Snydman, Laura A. McDermott, P. B. Iannini, Gale B. Hill, Timothy Cleary, J. P. O'keefe, C. L. Pierson, J. D. Rihs, S. M. Finegold> ;Clinical Therapeutics. 1992 Jan 1
• 43 citations
  Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clin...
  W. Eugene Sanders, James F. Morris, Paul Alessi, Alex T. Makris, Richard V. McCloskey, Gordon M. Trenholme, Paul B. Iannini, Marvin J. Bittner> ;The American Journal of Medicine. 1991 Sep 1
• 46 citations
  The antimicrobial susceptibility patterns of the Barteroides fragilis group in the United States, 1987
  N. A. Cornick, G J Cuchural, David R. Snydman, Nilda V. Jacobus, Paul B. Iannini, Gale B. Hill, Timothy Cleary, J. P. O'Keefe, Carl L. Pierson, Sydney M. Finegold> ;The Journal of Antimicrobial Chemotherapy. 1990 Jun 1
• 40 citations
  Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.
  G J Cuchural, F P Tally, Nilda V. Jacobus, T Cleary, S M Finegold, Gale B. Hill, P Iannini, J P O'Keefe, C Pierson> ;Antimicrobial Agents and Chemotherapy. 1990 Mar 1
• Join now to see all